MX2024006678A - Inhibidor de cdk4 para el tratamiento del cancer. - Google Patents

Inhibidor de cdk4 para el tratamiento del cancer.

Info

Publication number
MX2024006678A
MX2024006678A MX2024006678A MX2024006678A MX2024006678A MX 2024006678 A MX2024006678 A MX 2024006678A MX 2024006678 A MX2024006678 A MX 2024006678A MX 2024006678 A MX2024006678 A MX 2024006678A MX 2024006678 A MX2024006678 A MX 2024006678A
Authority
MX
Mexico
Prior art keywords
cancer
treatment
cdk4 inhibitor
administering
subject
Prior art date
Application number
MX2024006678A
Other languages
English (en)
Spanish (es)
Inventor
Jing Yang
Tun Tun Lin
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of MX2024006678A publication Critical patent/MX2024006678A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2024006678A 2021-12-02 2022-11-29 Inhibidor de cdk4 para el tratamiento del cancer. MX2024006678A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202163285320P 2021-12-02 2021-12-02
US202263382346P 2022-11-04 2022-11-04
US202263383969P 2022-11-16 2022-11-16
PCT/IB2022/061525 WO2023100070A1 (en) 2021-12-02 2022-11-29 Cdk4 inhibitor for the treatment of cancer

Publications (1)

Publication Number Publication Date
MX2024006678A true MX2024006678A (es) 2024-06-19

Family

ID=84440018

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024006678A MX2024006678A (es) 2021-12-02 2022-11-29 Inhibidor de cdk4 para el tratamiento del cancer.

Country Status (10)

Country Link
US (1) US20250041298A1 (cg-RX-API-DMAC7.html)
EP (1) EP4440576A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024542633A (cg-RX-API-DMAC7.html)
KR (1) KR20240112931A (cg-RX-API-DMAC7.html)
AU (1) AU2022400308B2 (cg-RX-API-DMAC7.html)
CA (1) CA3240993A1 (cg-RX-API-DMAC7.html)
IL (1) IL312650A (cg-RX-API-DMAC7.html)
MX (1) MX2024006678A (cg-RX-API-DMAC7.html)
TW (1) TWI922768B (cg-RX-API-DMAC7.html)
WO (1) WO2023100070A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024201340A1 (en) 2023-03-30 2024-10-03 Pfizer Inc. Kat6a as a predictive biomarker for treatment of breast cancer with a cdk4 inhibitor and an antiestrogen and methods of treatment thereof
KR20250164842A (ko) 2023-03-30 2025-11-25 화이자 인코포레이티드 Kat6a 억제제에 의한 치료를 위한 예측 바이오마커로서의 kat6a 및 이의 치료 방법
EP4719405A1 (en) 2023-06-02 2026-04-08 Pfizer Inc. Methods and modified dosing regimens comprising a cdk4 inhibitor for the treatment of cancer
WO2026133192A1 (en) * 2024-12-20 2026-06-25 Pfizer Inc. Combination therapies using cdk4 inhibitors with pd-1 axis binding antagonists

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4772247A2 (en) * 2013-08-14 2026-07-08 Novartis AG Combination therapy comprising ribociclib and fulvestrant for the treatment of cancer
CN118286225A (zh) 2018-04-26 2024-07-05 辉瑞公司 作为细胞周期蛋白依赖性激酶抑制剂的2-氨基-吡啶或2-氨基-嘧啶衍生物
WO2020157709A1 (en) * 2019-02-01 2020-08-06 Pfizer Inc. Combination of a cdk inhibitor and a pim inhibitor
PT4181920T (pt) * 2020-07-15 2025-11-04 Ctxt Pty Ltd Inibidor de kat6 e combinações para o tratamento do cancro da mama
CN116322693A (zh) * 2020-08-13 2023-06-23 辉瑞公司 组合疗法
MX2023003054A (es) * 2020-09-15 2023-04-05 Pfizer Formas solidas de un inhibidor de cdk4.
EP4288057A4 (en) * 2021-02-05 2025-03-12 Verastem, Inc. Combination therapy for treating abnormal cell growth

Also Published As

Publication number Publication date
IL312650A (en) 2024-07-01
AU2022400308B2 (en) 2026-02-12
JP2024542633A (ja) 2024-11-15
KR20240112931A (ko) 2024-07-19
EP4440576A1 (en) 2024-10-09
TWI922768B (zh) 2026-04-21
AU2022400308A1 (en) 2024-05-16
CA3240993A1 (en) 2023-06-08
TW202329970A (zh) 2023-08-01
WO2023100070A1 (en) 2023-06-08
US20250041298A1 (en) 2025-02-06

Similar Documents

Publication Publication Date Title
EP4327882A3 (en) Enpp1 inhibitors and their use for the treatment of cancer
MX2023002248A (es) Uso de inhibidores de sos1 para tratar neoplasias malignas con mutaciones de shp2.
PH12021551833A1 (en) Enpp1 inhibitors and methods of modulating immune response
ZA202407596B (en) Cancer treatments using mta-cooperative prmt5 inhibitors
MX2024012131A (es) Composicion farmaceutica, uso de la misma y metodo para tratar el cancer
ZA202300875B (en) Kat6 inhibitor methods and combinations for cancer treatment
MX2024004213A (es) Combinaciones de inhibidores de kras g12d con inhibidores de pi3ka y métodos de tratamiento relacionados.
MX2023001717A (es) Composiciones y metodos de agentes de la ruta del estres replicativo para el tratamiento del cancer.
WO2018102687A3 (en) Combination therapy for treating cancer
PH12022553501A1 (en) Alk2 inhibitors for the treatment of anemia
MX2024004214A (es) Combinaciones de inhibidores de kras g12d con irinotecán y métodos de tratamiento relacionados.
ZA202304965B (en) Combination therapy for treating cancer
MX2024014121A (es) Metodos y composiciones para el tratamiento del exceso de glucocorticoides
MX2024000674A (es) Agentes de union multiespecificos contra cd40 y cd137 en terapia de combinacion.
MX2020001727A (es) Terapia de combinacion.
BR112022026247A2 (pt) Método para aumentar a eficácia terapêutica de um agente de imunoterapia, método de tratamento de câncer e método de inibição do crescimento de uma célula de câncer
MX386735B (es) Terapia de combinacion para tratar tumores malignos.
WO2020132560A3 (en) Compositions and methods for cancer therapy
MX2025007373A (es) Tratamientos del cancer con inhibidores de prmt5 cooperativos con mta
MX2023006542A (es) Inhibidores de la vía cinasa jano 1 (jak1) para el tratamiento del vitiligo.
MX2022011725A (es) Metodos para tratar una lesion pulmonar con inhibidores de cgrp.
MX2025007378A (es) Inhibidores de ctps1 para usarse en el tratamiento de cancer deficiente de ctps2
MX2020008881A (es) Métodos de tratamiento contra el cáncer que comprenden inhibidores de chk1.
MX2022008532A (es) Inhibidores de hidrocarburo de arilo (ahr) y usos de estos.
MX2025011364A (es) Metodo de tratamiento de cancer de mama en estadio inicial con ribociclib en combinacion con un inhibidor de la aromatasa